Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy
Gerald M. Fenichel(Vanderbilt University), Bradley Wilson(Strong Memorial Hospital), Alan Pestronk(Washington University in St. Louis), L. Signore(The Ohio State University), J. Florence(Strong Memorial Hospital), S. Pandya(Strong Memorial Hospital), Justin Robison(Vanderbilt University), Richard T. Moxley(MACOM (United States)), Jerry R. Mendell(Nationwide Children's Hospital), Jeanine Schierbecker, Wendy King(The Ohio State University), J. Philip Miller(Washington University in St. Louis), Michael H. Brooke, Robert C. Griggs(University of Rochester)
Cited by 266
Related Papers
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522